IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 394 filers reported holding IONIS PHARMACEUTICALS INC in Q2 2019. The put-call ratio across all filers is 1.38 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $13,253,466 | +4.9% | 292,184 | -5.1% | 0.51% | +5.6% |
Q2 2023 | $12,636,830 | +9.7% | 307,990 | -4.4% | 0.48% | +8.5% |
Q1 2023 | $11,518,323 | -4.5% | 322,281 | +1.0% | 0.45% | -13.4% |
Q4 2022 | $12,055,202 | +69.0% | 319,174 | +97.9% | 0.52% | +57.0% |
Q3 2022 | $7,132,000 | +3.3% | 161,246 | -13.5% | 0.33% | +17.1% |
Q2 2022 | $6,903,000 | -10.5% | 186,454 | -10.4% | 0.28% | +3.7% |
Q1 2022 | $7,710,000 | -36.6% | 208,158 | -47.9% | 0.27% | -30.4% |
Q4 2021 | $12,153,000 | -18.6% | 399,392 | -10.2% | 0.39% | -13.2% |
Q3 2021 | $14,921,000 | -18.0% | 444,887 | -2.5% | 0.45% | -19.3% |
Q2 2021 | $18,199,000 | -8.2% | 456,226 | +3.4% | 0.55% | -11.4% |
Q1 2021 | $19,830,000 | +2.3% | 441,054 | +28.7% | 0.62% | -4.9% |
Q4 2020 | $19,381,000 | +18.8% | 342,774 | -0.3% | 0.66% | -1.8% |
Q3 2020 | $16,320,000 | -18.8% | 343,952 | +0.9% | 0.67% | -23.6% |
Q2 2020 | $20,099,000 | +21.9% | 340,900 | -2.3% | 0.88% | -3.5% |
Q1 2020 | $16,493,000 | +0.5% | 348,834 | +28.5% | 0.91% | +31.8% |
Q4 2019 | $16,406,000 | -5.3% | 271,568 | -6.1% | 0.69% | -8.3% |
Q3 2019 | $17,326,000 | +50.8% | 289,198 | +61.7% | 0.75% | +41.2% |
Q2 2019 | $11,492,000 | -40.4% | 178,814 | -24.8% | 0.53% | -40.2% |
Q1 2019 | $19,290,000 | -32.5% | 237,645 | -55.0% | 0.89% | -35.0% |
Q4 2018 | $28,558,000 | +5.6% | 528,259 | +0.8% | 1.37% | +11.8% |
Q3 2018 | $27,039,000 | +24.4% | 524,218 | +0.5% | 1.22% | +42.5% |
Q2 2018 | $21,731,000 | +11.5% | 521,515 | +18.0% | 0.86% | +9.1% |
Q1 2018 | $19,489,000 | -16.6% | 442,125 | -4.8% | 0.79% | -12.2% |
Q4 2017 | $23,367,000 | -23.8% | 464,560 | -23.1% | 0.90% | -22.8% |
Q3 2017 | $30,646,000 | -10.8% | 604,455 | -10.5% | 1.16% | -6.5% |
Q2 2017 | $34,342,000 | +6.6% | 675,088 | -15.8% | 1.24% | +13.3% |
Q1 2017 | $32,215,000 | -26.9% | 801,376 | -13.0% | 1.10% | -33.0% |
Q4 2016 | $44,060,000 | +16.4% | 921,174 | -10.9% | 1.63% | +18.0% |
Q3 2016 | $37,867,000 | +18.6% | 1,033,481 | -24.6% | 1.38% | +53.5% |
Q2 2016 | $31,939,000 | +27.6% | 1,371,376 | +121.9% | 0.90% | +28.9% |
Q1 2016 | $25,024,000 | +94.5% | 617,886 | +197.4% | 0.70% | +109.6% |
Q4 2015 | $12,866,000 | – | 207,757 | – | 0.33% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Bellevue Group AG | 9,930,245 | $396,117,000 | 3.87% |
Sicart Associates LLC | 368,409 | $14,696,000 | 3.50% |
Camber Capital Management LP | 2,000,000 | $79,780,000 | 2.69% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 181,781 | $7,251,000 | 1.91% |
SECTOR GAMMA AS | 263,488 | $10,511,000 | 1.86% |
Parkman Healthcare Partners LLC | 136,380 | $5,440,000 | 1.19% |
Eversept Partners, LP | 442,000 | $17,631,380 | 1.18% |
Affinity Asset Advisors, LLC | 75,000 | $2,992,000 | 1.07% |
TANAKA CAPITAL MANAGEMENT INC | 16,661 | $665,000 | 0.90% |
Sonora Investment Management, LLC | 168,665 | $6,728,000 | 0.88% |